This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

NEW YORK (TheStreet) -- Apple  (AAPL) may be Monday's big newsmaker with its Worldwide Developer Conference. But traders on StockTwits.com aren't waiting for Tim Cook and Co. to get started. Instead, they're watching announcements from small drug companies on medication trials and tuning in to rumors about big pharma buyouts.

And, so far today, their attention is paying off. 

The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming | http://stks.co/c0cBX $MNKD $OREX $IBB $BDSI #biotech ? Scott Matusow (@ScottMatusow) Jun. 2 at 08:58 AM

Drug companies Ariad Pharmaceuticals  (ARIA), MannKind (MNKD), NPS Pharmaceuticals  (NPSP) and Pharmacyclics  (PCYC) were the top trending tickers on StockTwits.com Monday morning. They were joined on the trending bar of the dozen most discussed stocks by two biotech ETFs, iShares Nasdaq Biotechnology  (IBB) and SPDR S&P Biotech  (XBI).

Apple made the list too, due to hype over what management could reveal about the company's product pipeline and plans for Beats Electronics. But many on StockTwits.com said that excitement was misplaced. Apple, they noted, has a history of disappointing WWDC expectations. The stock has declined after eleven of the past conferences.

$AAPL during WWDC , since 2003 & blog with details -> http://stks.co/g0fqq 11/11 losers for longs http://stks.co/s0Nqd ? Kora Reddy (@paststat) Jun. 1 at 09:35 AM

Investors on StockTwits were most interested in Ariad Pharmaceuticals. The company topped the StockTwits trending ticker bar with news that a drug to treat certain types of gastrointestinal tumors had positive results in early Phase II clinical trials. The FDA is lifting a partial ban that had restricted the company's ability to enroll new human test subjects.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs